SOURCE-LINKED STUDY SUMMARY
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Abstract summarizedQuality not appraised
- What was studied
- This 56-week randomized, double-blind trial compared daily liraglutide 3.0 mg, liraglutide 1.8 mg, and placebo; every group also received a calorie deficit and increased physical activity.
- Who / model studied
- The trial randomized 846 adults with overweight or obesity and type 2 diabetes at 126 sites in nine countries.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- At week 56, mean weight loss was 6.0%, 4.7%, and 2.0%, respectively. Gastrointestinal disorders were more common with 3.0 mg liraglutide; no pancreatitis was reported.
- Limitations & context
- Only 12 weeks of off-drug observation followed treatment, and the authors called for longer-term efficacy and safety research.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jama.2015.9676